Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18794867 | 0.87 | MAOB (0.64) | MAOBBRD4CREBBPNR3C2MEN1 | |
| SCHEMBL6757684 | 0.86 | KIF11 (0.50) | ADRB2ADRB1DRD4DRD3PARP1 | |
| SCHEMBL6295489 | 0.84 | MAOB (0.62) | MAOBBRD4CREBBPNPC1RAB9A | |
| SCHEMBL18794868 | 0.84 | MAOB (0.48) | MAOBBRD4CREBBPNR3C2MEN1 | |
| SCHEMBL21412923 | 0.80 | MAOB (0.46) | MAOBARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL704966 | 0.76 | MMP12 (0.55) | NR3C2PKMKMT2ASMN1; SMN2PARP1 | |
| SCHEMBL5496459 | 0.74 | MAOB (0.61) | MAOBCREBBPNR3C2NPC1RAB9A | |
| SCHEMBL13932091 | 0.74 | NR3C2 (0.58) | NR3C2PKMKMT2ASMN1; SMN2PARP1 | |
| SCHEMBL4259476 | 0.74 | NR3C2 (0.58) | NR3C2PKMKMT2ASMN1; SMN2PARP1 | |
| SCHEMBL24508418 | 0.74 | PDE3B (0.57) | MAOBBRD4CREBBPADRB2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428030-B2 | Heterocycle derivatives and their use for the treatment of CNS disorders | Trillium Therapeutics (CA) | 2019-10-01 | — | — | US | claimed |
| US-20180312480-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-11-01 | — | — | US | claimed |
| EP-3371154-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | Trillium Therapeutics Inc. (CA) | 2018-09-12 | — | — | EP | claimed |
| WO-2017070796-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-05-04 | — | — | WO | claimed |
| WO-2021231933-A1 | ANTI-EPILEPTIC PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NEUCYTE PHARMACEUTICALS (US) | 2021-11-18 | — | — | WO | disclosed |
| US-10428030-B2 | Heterocycle derivatives and their use for the treatment of CNS disorders | Trillium Therapeutics (CA) | 2019-10-01 | — | — | US | disclosed |
| EP-3371154-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | Trillium Therapeutics Inc. (CA) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017070796-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017070796-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312480-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, ACHE, CNR1 | MAOB 164/4885BRD4 1026/4885CREBBP 125/4885 |
| US-10428030-B2 | Heterocycle derivatives and their use for the treatment of CNS disorders | GRIN2C, ACHE, CNR1 | MAOB 164/4885BRD4 1026/4885CREBBP 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.